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Autologousbonegraftingisthemosteﬀectivetreatmentforlong-bonenonunions,butitposesconsiderableriskstodonors,neces-
sitatingthedevelopmentofalternativetherapeutics.Poly(ethyleneglycol)(PEG)microencapsulationandBMP2transgenedelivery
arebeingdevelopedtogethertoinducerapidboneformation.However,methodstomakethesetreatmentsavailableforclinicalap-
plications are presently lacking. In this study we used mesenchymal stem cells (MSCs) due to their ease of harvest, replication
potential, and immunomodulatory capabilities. MSCs were from sheep and pig due to their appeal as large animal models for
bonenonunion.WedemonstratedthatcryopreservationofthesemicroencapsulatedMSCsdidnotaﬀecttheircellviability,adeno-
viralBMP2production,orabilitytoinitiateboneformation.Additionally,microspheresshowednoappreciabledamagefromcryo-
preservation when examined with light and electron microscopy. These results validate the use of cryopreservation in preserving
the viability and functionality of PEG-encapsulated BMP2-transduced MSCs.
1.Introduction
Bone is the second most transplanted tissue behind blood
transfusions [1] with 500,000 people in the US and 2.2 mil-
lion people worldwide receiving bone grafts per year [2].
Autologous bone grafting is currently considered the gold
standard for treating nonhealing fractures [3], but multiple
featuresmake it less than ideal for long bone nonunion treat-
ment. The most promising graft donor site, the iliac crest,
is available in limited quantities [4]. Since long bone
nonunions can require up to 30mLs of marrow, the amount
harvested from the iliac crest can be insuﬃcient [5]. Bone
grafting presents considerable risks to patients by increased
surgical times and blood loss [6], with 1/3 of patients experi-
encing chronic pain 24 months after transplant [7], and reci-
pients are at increased risk for donor site instability and frac-
tures [8]. Additionally, large bone defects, like those received
by soldiers injured in combat [9, 10], often do not heal
without surgical intervention and can end in an undesirable
o u t c o m es u c ha sa m p u t a t i o n[ 11].2 International Journal of Biomaterials
Bone morphogenetic protein 2 (BMP2) is a potential
therapeutic that can ﬁll the need for bone healing. Recom-
binant BMP2 can induce rapid ossiﬁcation in orthopedic
applications [12, 13] but has a relatively short half-life, must
be administered at high dosages, and continually maintained
to promote extensive and expedited bone regeneration [14–
16]. Having a fast and maintained release/production of
BMP2 as an oﬀ the shelf therapeutic might be used without
the morbidity associated with bone grafting, reduce recovery
time, and minimize the need for future surgeries. Mesenchy-
malstemcells(MSCs)couldbeavectorfordeliveringBMP2;
MSCs have several potential advantages: they can be easily
harvested from adult bone marrow [17] and adipose tissue
[18, 19], are immunomodulatory [20–22], have allogeneic
tolerability [21], are easily expanded in vitro, and can dif-
ferentiate into bone even after long-term culture [19, 23].
Cellular encapsulation with genetically engineered cells
producing BMP2 in a PEG hydrogel for bone regeneration
was developed to extend expression of BMP2 in vivo [24].
PEGisanattractivematerialforbiomedicalapplicationswith
biocompatibility in multiple tissues [25–29]. Additionally,
the mechanical properties of PEG can be altered to replicate
t h a to fs o f tt i s s u e[ 30, 31]. As soft tissue injury often
occurs at the same time as long-bone injury, healing in-
volves the regeneration of both tissues [32]. Mimicking in
vivo soft tissue has been shown to be more permissive for
physiological healing in creating an environment permis-
sive for angiogenesis [33], a vital component for correct
bone healing [34]. PEG also has the ability to be made bio-
degradable in tissues through manipulations of the peptide
sequences linking PEG moieties [35–38] or incorporation of
extracellular matrices [39] which makes the structure cleav-
ablethroughproteolytic processes,allowingthe polymer and
encapsulated cells to be removed by the body during the
healing process. Initial studies with BMP2-transduced cells
microencapsulated in PEG hydrogels have been shown to be
superior to unencapsulated cells through the extended pre-
sence of BMP2-producing cells at the site of treatment and
increased induction of heterotopic ossiﬁcation (HO) in the
mouse [40]. This therapy has applications in human medi-
cine for replacing or supplementing current technologies for
increasing the rate of bone healing; however, processes to
makethePEGhydrogel-microencapsulatedcellsavailablefor
immediate use are lacking.
C r y o p r e s e r v e dc e l l sc a nb es t o r e da s“ r e a d yt ou s e ”p r i o r
to the therapeutic application [41], and cryopreservation of
cells microencapsulated in PEG hydrogels would also en-
hance and widen their therapeutic uses because testing of
preparations could be conducted well in advance in con-
trolled good manufacturing practices (GMP) facilities for
distribution to the clinical setting. Cryopreservation of cells
microencapsulated in alginate has previously shown success
in maintaining cell viability, stem cell characteristics, and
cellular recovery [42–45]. Cryopreservation allows for thor-
ough testing of the encapsulated MSCs with the ability to
thaw samples for validating cell viability, therapeutic protein
concentration, sterility, and microbead integrity for ensuring
that the highest-quality production has been performed.
However, the post thaw eﬀects of PEG hydrogel microen-
capsulationoncellsurvival,transgeneexpression,microbead
integrity, and biological activity have not been previously
investigated.
Pigs and sheep are suitable models for human bone stud-
ieswithlong-bonedimensions[46,47]andstructure[48,49]
that are similar to humans. Pigs have been shown to have
similarities in bone remodeling [48] while sheep provide a
comparable model for bone in growth into osteoconductive
biomaterials [50]. Using MSCs isolated from both pigs and
sheepwehaveexploredthepossibilityofcryopreservingPEG
hydrogel-microencapsulated MSCs expressing BMP2. The
cryopreservationofthecellswithinthemicrospheresshowed
no reduction in viability in comparison to nonpreserved mi-
croencapsulatedMSCs,andtheencapsulatedcellularspheres
showed no physical damage resulting from cryopreservation.
Itwasalsofoundthatcelllinesfromvariousdonorsmayhave
diﬀerent potentials in genetic modiﬁcation and transgene
production. Using this process genetically modiﬁed cryopre-
served MSCs producing BMP2 maintained function as seen
through initiation of bone formation in an in vivo model for
HO. While optimization for increasing cell viability in PEG
is still required, these results demonstrate that PEG hydrogel
microspheres have the potential to be manufactured for “oﬀ-
the-shelf” therapeutic use.
2.MaterialandMethods
2.1. MSC Isolation and Culture. Porcine MSCs were isolated
previously [51], and ovine MSCs were isolated with the same
plate adherency techniques from healthy female ewes as pre-
viously described. Brieﬂy, MSCs were isolated from bone
marrow aspirates with 0.25mLs acid citrate dextrose per mL
of bone marrow. MSCs were plated by mixing in a 3/5 ratio
with MSC culture medium: Alpha-Minimum Essential Med-
ium (Gibco), 10% deﬁned fetal bovine serum (Hyclone),
2mM L-glutamine, 50U/mL penicillin (Pen), 50μg/mL stre-
ptomycin (Strep; all from Gibco/Invitrogen), and plating on
tissue culture ﬂasks. Cultures were maintained at 37◦C
and at 5% CO2. MSCs were harvested using 0.05% trypsin
(Gibco) and replated at 5,000cells/cm2 upon reaching 80–
90% conﬂuency (60,000–75,000cells/cm2).
2.2. Lineage Diﬀerentiation. Diﬀerentiation was performed
using previously established protocols [51]w i t hm o d e r a t e
alterations: for adipogenic and osteogenic diﬀerentiation,
36,000cells/cm2 wereplatedin6-wellplates.MSCswereallo-
wed to reach conﬂuency and then switched to adipogenic or
osteogenic medium: adipogenic diﬀerentiation was ini-
tiated in induction medium: Dulbecco’s Modiﬁed Eagle
Medium (DMEM) high glucose (Hyclone), Pen/Strep, 1μM
dexamethasone, 10μg/mL insulin, 200μM indomethacin,
500μM 3-isobutyl-1-methyl-xanthine (Sigma), and 10%
FBS (Hyclone) for 3 days followed by 14 days in diﬀeren-
tiation medium: DMEM high glucose, Pen/Strep, 10μg/mL
insulin,and10%FBS.Diﬀerentiatedplateswerestainedwith
0.7% Oil Red O. Osteogenic diﬀerentiation was performed
using HyClone Advance STEM Osteogenic Diﬀerentiation
kit(ThermoScientiﬁc)withmediumchangeseverythirdday
for 21 days, and samples were stained with Von Kossa. ForInternational Journal of Biomaterials 3
chondrogenic diﬀerentiation potential validation of MSCs,
3 × 106 cells were pelleted in 15mL conical tubes and then
changed to chondrogenic medium DMEM (high glucose),
100nM dexamethasone, Pen/Strep, 50μg/mL ascorbic acid,
40μg/mL L-proline, 1 × ITS + 1 supplement (recombinant
human insulin, human transferring, sodium selenite, bovine
serum albumin, and linoleic acid), 1mM sodium pyruvate
(all from Sigma), and 10ng/mL TGF-β3 (R&D Systems).
Medium was changed every third day for 14 days. Micro-
masses were stained with Alcian Blue.
2.3. Proliferation. Proliferation was determined using man-
ual cell counts with 0.04% trypan blue (Sigma) live/dead ex-
clusion staining, and only live MSCs were counted. MSCs
were plated at 6,000cells/cm2 and harvested for counts 12
hours following plating. This initial count was deemed time
0, and MSCs were harvested and counted at 12, 24, 36, 48,
and 60 hours after the initial count. All counts were per-
formed in triplicate.
2.4. Microencapsulation. Using techniques previously des-
cribed [40, 52], MSCs were harvested using 0.05% trypsin
and counted on a hemocytometer using 0.04% Trypan Blue
(Sigma) staining for live/dead exclusion. 3.5 × 104 MSCs/μL
were suspended in an aqueous hydrogel solution containing
0.1g/mL 10kDa PEG diacrylate (PEGDA), 1.5% (v/v) tri-
ethanolamine/HEPES-buﬀered saline,37mM 1-vinyl-2-pyr-
rolidinone, 0.1mM eosin y, and 9mM pluronic acid. For
photo initiation, 1.17M 2,2-dimethoxy-2-phenyl acetophe-
none was dissolved in 1-vinyl-2-pyrrolidinone, and 3μLo f
this solution was added per mL of sterile mineral oil (Sigma-
Aldrich). Hydrogel/cell suspension was mixed with mineral
oil containing the photoinitiator and vortexed for 2 seconds
while being exposed to white light from a Metal Halide Illu-
minator (Edmonds Optics) followed by another 18-second
exposure with mild mixing. Microencapsulated MSCs were
separatedfromtheoilwithfourwashesinMSCculturemed-
ium with 5-minute centrifugation at 1350RPM and decant-
ing between washes.
2.5. Viability Assays. Cell viability was assessed using the
LIVE/DEAD Viability/Cytotoxicity Kit for Mammalian
MSCs (Invitrogen). Images were taken using TCS SP5 Spec-
tral Confocal Microscope (Leica). 3 sets of images were taken
per condition with 30 images in each set with an average of
87,210 cells being counted in each treatment using Image J
(NIH).
2.6. Cryopreservation and Thawing. MSCs and microspheres
werefrozeninMSCculturemediumcontaining10%DMSO.
The MSCs were frozen in controlled rate freezing containers,
Mr. Frostys (Nalgene labware) for 4–24 hours at −80◦Ca n d
then transferred to liquid nitrogen. Vials were thawed in a
37◦C water bath with constant swirling. The MSCs were
resuspended with medium immediately following loss of
ice from cell/microsphere suspension. To limit confounding
factors microspheres were thawed using a ratio of twenty
percentphysicalcellloss.Thisnumberwasestablishedonthe
percentage of cells lost during cryopreservation and thawing
processes.
2.7. Adenoviral Transduction Optimization and BMP2 Quan-
tiﬁcation. First-generation human type 5 adenoviruses con-
taining the E1–E3 deletion were constructed with human
cDNA for BMP2 inserted in the E1 region. MSCs were har-
vested and plated one day prior to transductions. Transduc-
tions were performed as described previously [51]w i t h
minor changes. Upon reaching a density of 36,000cells/cm2
the MSCs were prepared for transduction. To increase cell-
viral interactions transductions were performed in reduced
medium volumes. Medium was changed with replacement
of 32% of normal culture volume of MSC culture medium.
Transduction medium was made equaling 20% of normal
culture volume with Alpha MEM medium with 2mM L-glu-
tamine and mixed with 0.72% Genejammer (Agilent Tech-
nologies) and allowed to incubate for 5 minutes at room
temperature. The virus was then added to the transduc-
tion medium and allowed to incubate for 10 minutes at
room temperature. For optimization of BMP2 transduction,
transductions were performed using 5,000, 7,500, 10,000,
and 15,000vp/cell (See Supplementary Figure 1 in Supple-
mentary Material available online at doi: 10.1155/2012/
861794). The remaining experiments were performed with
15,000vp/cell. The transduction mixture was then added
to the cell culture dropwise around the plate. After four
hours the culture volume was brought up to normal vol-
ume with MSC culture medium. MSCs were harvested 24
hours after the transduction. The MSCs were replated at
36,000cells/cm2 or microencapsulated then replated at
36,000cells/cm2. BMP2 was quantiﬁed from harvested med-
ium using a BMP2 ELISA (R&D systems).
2.8.ScanningElectronMicroscopyandLightMicroscopy. Both
freshly prepared and cryopreserved microspheres containing
ovineMSCswereimmersionﬁxedusing2.5%glutaraldehyde
in PBS for one hour. The MSCs were washed three times
with PBS and postﬁxed in 1% osmium tetroxide diluted in
5% sucrose and PBS for 45 minutes. The microspheres were
washed three times with distilled water and then carried
through an alcohol dehydration series. The MSCs were criti-
cally point-dried using a Samdri model 780-A (Tousimis). A
153 ˚ A thick coating of gold was placed on the samples using
SPI Module Sputter Coater (Structure Probe). The images
were taken on 1450EP environmental Scanning Electron
Microscope (Carl Zeiss).
2.9. Heterotopic Bone Assay. All animal studies were per-
formedwithBaylorCollegeofMedicineInstitutionalAnimal
Care and Use Committee approval. Female nonobese dia-
betic/severely compromised immunodeﬁcient mice (NOD/
SCID; 8–12 weeks old; Charles River Laboratories) were in-
jected with 3 × 106 microencapsulated MSCs either freshly
prepared or cryopreserved and thawed from ovine B MSCs.
Microspheres were injected into the hind-limb quadriceps of
4m i c ep e rg r o u p( n = 8). Animals were euthanized at 2
weeks and X-rayed. The tissue was then harvested and ﬁxed
in formalin.
2.10. Microcomputed Tomography. Microcomputed tomog-
raphy (micro CT) was obtained from the legs injected with4 International Journal of Biomaterials
the microsphere preparations. The legs were examined at a
15mm resolution (eXplore Locus SP; GE Healthcare, Lon-
don, ON, Canada). A hydroxyapatite phantom was scanned
alongside each specimen and was used to convert the scan
data from arbitrary units to units of equivalent bone density.
Thethree-dimensionalregionofinterestwasdeﬁnedforeach
animal to separate HOs from the normal skeletal structures.
The threshold for tissue within the region of interest was
set to exclude any tissue with a density less than 100mg/cc,
and the volume of tissue was calculated as a total amount of
mineralized tissue.
2.11. Graphical Representation and Statistics. Graphs were
made in Prism (Graphpad), and all statistics were also done
in Prism. Statistics comparing BMP2 production were per-
formed using 2-way ANOVA with Bonferonni posttest. Via-
bility comparisons were done with 1-way ANOVA using
Tukeys posttest. Doubling times were calculated using the
exponential growth equation in Prism, and comparison of
doubling times was done with 1-way ANOVA with Bonfer-
roni posttest. HO volumes were compared using a Student’s
t-test.
3. Results
Lineage diﬀerentiation of porcine MSCs used in this study
was previously validated [51]. Ovine MSCs isolated through
plate adherence from bone marrow aspirates were diﬀerenti-
ated using previously developed protocols and were capable
of osteogenic, chondrogenic, and adipogenic diﬀerentiation
(Figures 1(a), 1(b),a n d1(c)). Ovine MSCs underwent 21
days of osteogenic diﬀerentiation and showed evidence of
calcium deposition as seen through Von Kossa silver nitrate
staining (Figure 1(a)). After 14 days of chondrogenic diﬀer-
entiation the micromasses exhibited sulfate proteoglycans as
seen through Alcian Blue staining (Figure 1(b)), indicating
the presence of chondrocytes. At 17 days of adipogenic diﬀe-
rentiation, lipid droplets were visible within MSCs through
Oil Red O staining (Figure 1(c)), validating the capacity of
these derived MSCs to diﬀerentiate into all three mesenchy-
m a ls t e mc e l ll i n e a g e s .
During the expansion phase it was noted that the ovine A
MSCs proliferated more rapidly than the ovine B MSCs and
porcine MSCs. To examine the diﬀerences in proliferation
rates of the cell lines, 5 counts at 12 hour intervals were used
to determine proliferation rates. Ovine A MSCs had a doubl-
ing time of 15.2 (±0.7) hours (R2 = 0.9813), ovine B MSCs
had a doubling time of 19.7 (±1.5) hours (R2 = 0.9867),
and porcine MSCs had a doubling time of 34.5 (±3.2) hours
(R2 = 0.9755). The doubling times from each line were all
statistically diﬀerent (P<0.05) (Figure 1(d)). To under-
stand the eﬀect transduction had on the proliferation rates,
doubling times of ovine A and ovine B MSCs were
determined by plating the MSCs 24 hours after transduc-
tion and counting as described for the nontransduced cells.
Adenoviral BMP2-transduced ovine A and ovine B MSCs
showedasigniﬁcantreduction intheproliferationratesfrom
the nontransduced MSCs (P<0.05) (Figure 1(e))w i t h
a doubling time of 24.1 (±2.1) hours (R2 = 0.9827) and 25.4
(±2.2 hours) (R2 = 0.9820), respectively.
To determine the ability of the MSC to produce BMP2
following adenoviral transduction and the eﬀect of cryop-
reservation on BMP2 production, monolayers of MSCs were
transduced with 15,000 viral particles/cell. 15,000vp/cell was
chosen based on the highest BMP2 production from opti-
mization of 5,000, 7,500, 10,000, and 15,000vp/cell (P<
0.05) (Supplementary Figure 1). The MSCs were replated 24
hours after transduction or cryopreserved. Medium was har-
vested from cultures every 24 hours for 72 hours and quanti-
ﬁed for BMP2 expression (Figure 1(f)).The celllines showed
a signiﬁcant donor eﬀect (P<0.001) with ovine A MSCs
producing the most BMP2. Ovine B MSCs had a signiﬁcant
increase in BMP2 expression from cryopreserved samples at
48 and 72 hours (P<0.001).
To examine the eﬀect of cryopreservation on the survival
of microencapsulated MSCs, the viability of MSCs micro-
encapsulatedinPEGhydrogelswasassessedusinga live/dead
assay which stains the cytoplasm of live MSCs with calcein
AM (Figures 2(a), 2(e), 2(i), and 2(l)) and the dead MSCs
DNA with Ethidium Homodimer (Figures 2(b), 2(f), 2(J),
and 2(m)). No statistical diﬀerence was seen in the cell viabi-
lity between the freshly prepared MSCs and the cryopreser-
ved MSCs, but a signiﬁcant reduction in cell viability was
observed between day 0 and day 4 after-microencapsulation
in both freshly prepared and cryopreserved microspheres
(P<0.0001) (Figures 2(d) and 2(h)). When microencapsu-
lated, BMP2-transduced MSCs produced a reduced quantity
of BMP2 (Figure 3(a)) when compared to monolayer BMP2-
transduced MSCs (Figure 1(b))a t7 2a n d9 6h o u r sa f t e r
transduction (P<0.05). Porcine microencapsulated BMP2-
producing MSCs showed an increase in BMP2 production
at 72 (P<0.01) and 96 hours (P<0.001) following trans-
duction, and cryopreserved ovine B MSCs had a reduction
in the quantity of BMP2 produced at 72 and 96 hours after
transduction (P<0.01) (Figure 3(a)).O vi n eAMSC shadn o
diﬀerence between the cryopreserved and freshly prepared
microencapsulatedMSCBMP2;withintheovinelines, ovine
A MSCs produced signiﬁcantly more BMP2 than ovine B
MSCs at 96 hours after transduction (P<0.01) under both
conditions (Figures 1(b) and 3(a)). BMP2 transduction has
no eﬀect on viability immediately following microencapsu-
lation (Figure 3(b)), but the BMP2 microencapsulated MSCs
didhavereducedviabilityatday4(P<0.05)whencompared
to the nonmodiﬁed MSCs (Figure 3(c)).
The integrity of the microspheres was examined follow-
ing cryopreservation through scanning electron microscopy
and light microscopy. The light microscopy images (Figures
4(a) and 4(d)) show the perimeter of the bead containing
encapsulated ovine MSCs as being one contiguous sur-
face with no rough edges. Additionally high-magniﬁcation
images of the ovine microspheres demonstrated that the
spheres possess uniform surfaces with no loss of integrity
(Figures 4(b) and 4(e)). Cryopreservation did not result in
anychangesinthesurfacemorphologyofmicroencapsulated
MSCs (Figures 4(c) and 4(f)).
In the rodent model for HO, BMP2-transduced encap-
sulated microspheres are capable of producing bone as seenInternational Journal of Biomaterials 5
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Figure 1: Characterization of ovine MSCs and proliferation and BMP2 transduction of ovine and porcine MSCs: ovine MSCs (a) osteogenic
diﬀerentiation is seen through dark staining of calcium depositions by Von Kossa silver nitrate staining. (b) Chondrogenic diﬀerentiation
withchondroitinsulfateproteoglycansstainedbluewithAlcianBluestaining,and(c)adipogenicdiﬀerentiationasseenthroughintracellular
lipid staining with Oil Red O. (d) Ovine A, ovine B, and porcine cell line proliferation rates. (e) Proliferation rates of ovine A and ovine B
following transduction with 15,000vp/cell of adenoviral BMP2. (f) Transduction with 15,000vp/cell adenoviral BMP2 production from
ovine and porcine MSCs both with and without cryopreservation.
through radiographs two weeks following injection (Figures
5(a) and 5(d)). Additionally, volume rendering analysis
through micro-CT of the HO produced by the freshly prepa-
redmicrospheres(Figure 5(b))andthecryopreservedmicro-
spheres (Figure 5(e)) did not exhibit diﬀerences in mineral-
ized tissue volume (Figure 5(c); (P = 0.67)).
4. Discussion
A major hurdle in developing clinical treatments for bone
injury is establishing methods to render the therapeutics
widely applicable and readily available for clinical use. The
recipient of a cell therapy, like organ transplantation, is at
risk for graft rejection, and research has increased in cell
microencapsulation as an immunoisolation technique in
favor of immunosuppressants to modulate this immunolo-
gical process [27, 53, 54]. 10kDa PEGDA was chosen for this
project based on previous data supporting its ability to allow
proteins of 66,776kDa molecular weight to pass through
polymerized PEGDA, but still prevent the passage of IgG
antibodies through the structure [55]. In this study we de-
monstrated for the ﬁrst time that primary MSCs could suc-
c e s s f u l l yb ec r y o p r e s e r v e di nP E Gh y d r o g e lm i c r o s p h e r e s .
This is a valuable progression in the movement of PEG
hydrogel microencapsulation procedures from the bench top
to the bedside. The combined microencapsulation and cryo-
preservation method yields high MSC viability after thaw,
similar to alginate and sodium cellulose sulfate cell microen-
capsulation techniques [44, 56–58]. However, unlike previ-
ous reports of damage in alginate microcapsules during the6 International Journal of Biomaterials
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Figure 2: Viability of MSCs on day 0 and 4 after encapsulation with and without cryopreservation: MSCs were stained with calcein AM for
live (green) and ethidium homodimer for dead (red). On the day of microencapsulation ovine A MSCs stained for (a) live, (b) dead, and (c)
overlay.Andonday4followingmicroencapsulation(e)ovineAMSCsstainedforlive,(f)dead,and(g)overlay.(d)Graphicalrepresentation
of counts of 90 images. Cryopreserved ovine A encapsulated MSCs on day of thaw (i) live, (j) dead, and (k) overlay. Day 4 postthaw ovine A
MSCs stained for (l) live, (m) dead, and (n) overlay. (h) Graphical representation of counts of 90 images (averaging 87,000 cells per group).
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Figure 4: Structural analysis of freshly prepared and cryopreserved encapsulated MSCs: (a) phase contrast of microencapsulated ovine A
MSCs showed clear borders on microbeads. (b) SEM of MSC microbeads showed a uniform surface. (c) SEM of MSC microbeads of all sizes
showeduniformstructure.(d)PhasecontrastofcryopreservedmicroencapsulatedMSCsdidnotshowappreciabledamage.(e)SEMofcryo-
preserved MSC microbeads showed a uniform surface. (f) SEM of cryopreserved microencapsulated MSCs showed no damage to beads of
various sizes.8 International Journal of Biomaterials
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Figure 5: BMP2-transduced microencapsulated MSCs bone formation in a mouse model for heterotopic ossiﬁcation. 3 × 106 ovine B MSCs
transduced with 15,000vp/cell were injected into the hind limb of a NOD/SCID mouse. The resulting heterotopic ossiﬁcation was observed
by X-ray and MicroCT for (a) and (b) for freshly prepared BMP2 microencapsulated MSCs and (d) and (e) for cryopreserved BMP2 micro-
encapsulated MSCs. (c) The volume of the resulting heterotopic ossiﬁcation was not diﬀerent between the two groups.
cryopreservation process [11, 59, 60], PEG hydrogel micro-
spheres did not show any appreciable damage upon removal
from cryopreservation when examined by both light and
scanning electron microscopy. Compromises in the integrity
of the microsphere can result in exposure of the microencap-
sulated MSCs and initiation of an immune rejection [61].
The maintenance of integrity and cell viability seen with
the cryopreserved microencapsualted MSCs is likely due
to both the size and composition of the microbeads. Cry-
opreserved microencapsulated BMP2-transduced MSCs
maintained their potential to form bone in a mouse model
for HO, indicating that these preparations can be stored with
no adverse eﬀects on quality of the treatment. These features
will eventually allow for production of a human-based
product at GMP facilities with distribution to clinics. The
viability of the primary MSCs was adversely aﬀected by
adenoviral genetic modiﬁcation stressors in transduction
and microencapsulation processes. For microencapsulated
BMP2-transduced MSCs to be a viable treatment for long-
bone injury extended BMP2 production will be required
[16]. Here we show that the viability of the genetically mod-
iﬁed microencapsulated MSCs was reduced to less than 40%
by day 4 which may severely limit their therapeutic potential.
Both inclusion of extracellular matrix proteins [62]a n d
choosing cell lines with more substantial viability [40]a r e
two potential methods that can be incorporated to increase
cell viability and potentially increase the duration of BMP2
production. Additionally, the concentrations of Eosin Y, the
photosensitizer, and triethanolamine, the initiator, may in-
creasethelossofcellviability.Thesetwocompoundsarevital
for polymerization of the hydrogels, but at the concentra-
tions used are toxic to MSCs [63].
The MSC line used for adenoviral BMP2 transduction
can signiﬁcantly impact the amount of BMP2 expressed.
Since limited numbers of MSC lines between and within spe-
cies were used here, a speciﬁc conclusion among individual
MSC lines would be premature; however in general we found
signiﬁcant donor variation which aﬀected both the rates of
proliferation and BMP2 production from the MSC lines.
This suggests that cell line selection may have an impact on
the time required to expand cells in culture and the quantity
of therapeutic BMP2 produced. Since the amount of BMP2
expression and rate of proliferation followed the same trend,
a shorter cell cycle time may be an indicator of cell lines that
aremoreamenabletohigherratesoftransduction.Sinceade-
novirus is most eﬀective at transducing cells in the S phaseInternational Journal of Biomaterials 9
[64], cells with a shorter doubling time would be more likely
to pass through S phase in the presence of active virus. There
was less diﬀerence in BMP2 production between all lines fol-
lowing microencapsulation, but a diﬀerence between the
ovine lines was still observed. This again indicates that MSC
line-to-line variability signiﬁcantly impacts the amount of
BMP2 produced and that optimization of BMP2 expression
may need to be conducted for each batch or lot of MSC col-
lected regardless of prior validation.
Thecryopreservationprocessdidnotaﬀectthebiological
activity of the BMP2-transduced microencapsulated MSCs,
and the volume of the microencapsulated BMP2-producing
MSCs had similar quantities of induced heterotopic bone
as seen previously with BMP2-producing microencapsulated
ﬁbroblast cells in NOD/SCID mice [40]. This study, like
that of the ﬁbroblast studies, used NOD/SCID mice to pre-
vent interspecies rejection of the microencapsulated cells in
releasing foreign proteins in the host. These results indicate
that MSCs can be interchangeable with ﬁbroblast cells in
production of the therapeutic BMP2, and this ﬂexibility can
allow for the incorporation of immune modulatory charac-
teristics of the MSCs in combination with transgene expres-
sion.Ultimately,cryopreservationofmicroencapsulatedcells
allows for greater application of derived therapeutics. This
process facilitates the storage of sizable lots of character-
ized product for “oﬀ-the-shelf” regenerative cell therapies,
ensuringthesafestandmosteﬃcaciousapplicationofmicro-
encapsulated cellular therapy.
5. Conclusions
Microencapsulation of MSCs holds much promise for ther-
apeutics in diseases without current eﬀective treatments. To
move these treatments forward, methods for preserving and
long-term storage of microencapsulated MSCs to allow for
“oﬀ-the-shelf” therapeutics are necessary. The cryopreserva-
tion of MSCs microencapsulated in PEG hydrogels did not
reduce cell viability between the cryopreserved and freshly
preparedMSCs,bothwithandwithoutgeneticmodiﬁcation,
and did not demonstrate any physical damage resulting from
the cryopreservation process. Cryopreservation does not in-
duce any negative eﬀects on the microencapsulated MSCs
ability to form bone; however, the microencapsulated MSCs
did have reduced viability following adenoviral transduction
indicating a need for incorporating methods that increase
viability of microencapsulated MSCs to prolong protein pro-
duction. Donor-to-donor variability results in signiﬁcant
diﬀerences in transgene production, making cell line choice
important for optimizing gene expression. This demons-
trates that genetically engineered microencapsulated MSCs
havepotentialforbeingusedasatreatmentmethodforclini-
cal applications.
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